Johnson & Johnson Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
Johnson & Johnson (JNJ) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 3.30% for the 12-month period ending 2025-12-28, per its 10-K filed 2026-02-11.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2026-02-11
- Johnson & Johnson share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2025 was 3.30%, a 6.45% increase from fiscal 2024.
- Johnson & Johnson share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2024 was 3.10%, a 6.90% increase from fiscal 2023.
- Johnson & Johnson share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2023 was 2.90%, a 7.41% increase from fiscal 2023.
- Johnson & Johnson share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2023 was 2.70%, a 8.00% increase from fiscal 2022.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month |
|---|---|
| 2025-12-28 | 3.30% 10-K · filed 2026-02-11 |
| 2024-12-29 | 3.10% 10-K · filed 2026-02-11 |
| 2023-12-31 | 2.90% 10-K · filed 2026-02-11 |
| 2023-01-01 | 2.70% 10-K · filed 2025-02-13 |
| 2022-01-02 | 2.50% 10-K · filed 2024-02-16 |
| 2021-01-03 | 2.60% 10-K · filed 2023-02-16 |
| 2019-12-29 | 2.80% 10-K · filed 2022-02-17 |
| 2018-12-30 | 2.70% 10-K · filed 2021-02-22 |
| 2017-12-31 | 2.90% 10-K · filed 2020-02-18 |
| 2017-01-01 | 3.10% 10-K · filed 2019-02-20 |
| 2016-01-03 | 2.90% 10-K · filed 2018-02-21 |
| 2014-12-28 | 3.10% 10-K · filed 2017-02-27 |
| 2013-12-29 | 3.40% 10-K · filed 2016-02-24 |
| 2012-12-30 | 3.60% 10-K · filed 2015-02-24 |
| 2012-01-01 | 3.60% 10-K · filed 2014-02-21 |
| 2011-01-02 | 3.30% 10-K · filed 2013-02-22 |
| 2010-01-03 | 3.30% 10-K · filed 2012-02-23 |
| 2008-12-28 | 2.90% 10-K · filed 2011-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |